Werbung

Bioscience Valuation BSV GmbH

BioScience Valuation (BSV) is a consulting company working at the intersection of life sciences and finance. BSV is a trusted partner for Pharma and Biotech companies and their investors, with a 500+ mandates track record of private and public clients in Europe, the US, and worldwide.
Since 2000, the company has been at the forefront of translating scientific innovation into financial value. Our services cover the entire spectrum of commercial, R&D and financial analyses and deliver unparalleled evidence-based assessments. Based on our profound subject expertise and comprehensive database coverage, our appraisals demonstrate the route to value creation from seed stage to IPO and beyond.
Our strategic alliances enable us to reach out into the US and other markets and to communicate client equity stories within the international investor community.

 

 


BSV at a glance:

Products/Services
BSV provides a broad range of services tailored to the specific needs of each client:

Pharmaceutical companies
• Implementation of value-driven R&D portfolio management
• Optimization of R&D productivity, resource/capacity planning
• Forecast of a drug´s sales potential, determination of project value and prioritization in the portfolio context
• Competitive intelligence
• Assessment of in-licensing candidates and potential M&A transactions

Biotech/Medtech companies
• Assessment and valuation of technology platforms, developement products, and the company’s growth potential
• Indication scoping (identification and prioritization of therapeutic indications based on the company’s technology)
• Definition of USP and outline of expected value evolution to create unique equity stories                          • Support of business development and fundraising campaigns
• Negotiation of term sheets and agreements to maximize value

Investors
• Opportunity scouting, support of internal due diligence
• Assessment of single assets and entire R&D programs
• Optimization of program/portfolio strategy
• Support of relationship building with US investor community

Strategic alliances
• LaVoie Health Science, USA (Boston, New York)
• FCF Fox Corporate Finance GmbH, Germany (Munich)

Date of Incorporation 2000

 


Contact:

Joachim M. Greuel, Ph.D., MBA, Managing Director,
Co-Founder
Kerstin M. Bode-Greuel, MD, PhD.
Managing Director,
Co-Founder
Address Am Zigeunerbergl 3
82491 Grainau
Telephone/Telefax +49 8821 966 979-10 /-29
Email contact@bioscience-valuation.com
Web Address www.bioscience-valuation.com
Social Media LinkedIn

 

Beiträge von/mit Bioscience Valuation

Surging expected growth of drug approvals over the next decade

In March 2024, we reported a gradual increase of new drug approvals over the past 30 years, combined with an increasing focus on cancer,...

Finance Days: „What’s the value of data? We have to talk...

Am vergangenen Mittwoch und Donnerstag versammelten sich zahlreiche Expertinnen und Experten der Life Sciences auf den Finance Days der GoingPublic Media AG, ausgerichtet im...

Can biopharma’s drug-focused R&D strategy remain profitable?

Since the 1990s, there has been a shift in focus within pharmaceutical R&D. It resulted in placing greater emphasis on ­areas such as cancer,...

Finance Days: Kapital für Innovationen!

Der zweite Tag der Finance Days am Donnerstag, 11. April, widmet sich dem Thema „Wachstumskapital für die Life Sciences“ – ein immer noch spannendes,...

„What’s the deal“ in Smarter Medizin, Nachhaltigkeit und Finanzierung?

Am Mittwoch und Donnerstag, 10. und 11. April, versammeln sich wieder Expertinnen und Experten der Life Sciences auf den Finance Days der GoingPublic Media...